Amendments to the claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

CLAIMS

What is claimed is:

(Original) A compound of formula (I):

$$R^1$$
— Z — Q — N
 R^2
(I)

wherein

 R^1 represents optionally substituted C_{4-12} alkyl, optionally substituted C_{2-6} alkylaryl, or optionally substituted 5- or 6- membered aryl or heteroaryl;

Z represents a bond, CH₂, O, S, SO, SO₂, NR⁴, OCR⁴R⁵, CR⁴R⁵O, or Z, R¹ and Q together form an optionally substituted fused tricyclic group;

Q represents an optionally substituted 5- or 6- membered aryl or heteroaryl ring;

X represents COR3 or N(OR8)COR9:

R² represents SO₂R¹⁰ or SO₂NR¹⁰R¹¹;

R³ represents OR⁶, NR⁶R⁷ or NR⁶OH;

R⁴ and R⁵ each independently represents H, C₁₋₆ alkyl or C₁₋₄ alkylaryl;

R⁶ and R⁷ each independently represents H, C₁₋₆ alkyl, or C₁₋₆ alkyl substituted with one or more heteroaryl groups, or R⁶ and R⁷ together with the nitrogen atom to which they are attached form a 5- or 6- membered ring which may optionally include 1 or more further heteroatoms selected from O, S and N;

R⁸ and R⁹ each independently represents H or C₁₋₆ alkyl;

R¹⁰ and R¹¹ each independently represents H or C₁₋₆ alkyl; and and physiologically functional derivatives thereof, with the exception of N-(ethoxycarbonyl)-N-[4-(1H-tetrazol-1-yl)phenyl]glycine.

(Original) A compound as claimed in claim 1 of formula (la):

International Application No. PCT/EP2004/006553
International Filing Date: 16 June 2004

wherein R^{10} represents H or C_{1-6} alkyl;

R¹² represents H, halo, CF₃, cyano, OCF₃, nitro, OR¹³, SR¹³, COR¹³ or C₁₋₆ alkyl; R¹³ represents C₁₋₆ alkyl or C₁₋₄alkylaryl; and physiologically functional derivatives thereof.

- 3. (Cancelled)
- 4. (Currently Amended) A method for the treatment of a human or animal subject suffering from or susceptible to an autoimmune disorder or an inflammatory condition which method comprises administering to said human or animal subject an effective amount of a compound as claimed in claim 1-or claim 2.
- 5. (Cancelled)
- 6. (Currently Amended) A pharmaceutical composition comprising a compound as claimed in claim 1 or claim 2 and a pharmaceutically acceptable carrier therefor, and optionally one or more other therapeutic agents.
- 7. (Original) A process for the preparation of compounds of formula (I) as defined in claim 1, which process comprises:
- (A) for the preparation of a compound of formula (I) wherein Z represents a bond and R^1 represents an optionally substituted C_{2-6} alkylaryl or an optionally substituted 5- or 6-membered aryl or heteroaryl, reacting a compound of formula (II):

wherein R², Q and X are as previously defined for formula (I) and L represents a leaving group, with a reagent suitable to introduce the group R¹; or

(B) for the preparation of a compound of formula (I) wherein Z represents a bond and R^1 represents an optionally substituted C_{4-12} alkyl, reacting a compound of formula (III):

International Application No. PCT/EP2004/006553 International Filing Date: 16 June 2004

$$H-Q$$
 N
 R^2
(III)

wherein R^2 , Q and X are as previously defined for formula (I), with a reagent suitable to introduce the group R^1 ; or

(C) for the preparation of a compound of formula (I) wherein Z represents O, S, SO, SO₂, NR^4 or OCR^4R^5 , and R^1 represents an optionally substituted C_{4-12} alkyl, reacting a compound of formula (IV):

wherein X, R² and Q are as previously defined for formula (I), and Y represents OH, SH, NR⁴H or HCR⁴R⁵, with a reagent suitable to introduce the group R¹ followed in the case where Y is SH by optional oxidation of the sulphide to the sulfoxide or the sulfone; or

(D) for the preparation of a compound of formula (I) wherein Z represents O, S, SO, SO₂, or NR⁴, and R¹ represents an optionally substituted C_{2-6} alkylaryl or an optionally substituted 5-or 6- membered aryl or heteroaryl, reacting a compound of formula (IV):

$$Y-Q$$
 N
 R^2
 (IV)

wherein X, R² and Q are as previously defined for formula (I), and Y represents OH, SH or NR⁴H, with a reagent suitable to couple to the group R¹, followed in the case where Y is SH by optional oxidation of the sulphide to the sulfoxide or the sulfone; or

(E) for the preparation of a compound of formula (I) wherein Z represents OCR⁴R⁵ and R¹ represents an optionally substituted C₂₋₆alkylaryl or an optionally substituted 5- or 6-membered aryl or heteroaryl, reacting a compound of formula (V):

International Application No. PCT/EP2004/006553 International Filing Date: 16 June 2004

$$L^{4} \xrightarrow{R^{5}} Q \xrightarrow{X} (V)$$

wherein X, R² and Q are as previously defined for formula (I) and L⁴ is a suitable leaving group, with a reagent suitable to introduce the group R¹-O; or

(F) for the preparation of a compound of formula (I) wherein Z represents CR⁴R⁵O, reacting a compound of formula (IV):

wherein R² and Q are as previously defined for formula (I), and Y represents OH, with a reagent suitable to introduce the group R¹CR⁴R⁵-; or

(G) for the preparation of a compound of formula (I) wherein Z represents CH₂, reacting a compound of formula (III):

$$H-Q-N$$
 R^2
(III)

wherein R^2 , Q and X are as previously defined for formula (I), with a reagent suitable to introduce the group R^1CH_2 ;

(H) reacting a compound of formula (VI)

$$R^{1}$$
 Z Q N H (VI)

International.Application No. PCT/EP2004/006553 International Filing Date: 16 June 2004

or a protected derivative thereof, wherein R^1 , Z, Q and X are as previously defined for formula (I), with a reagent suitable to introduce the group R^2 as previously defined for formula (I): or

(J) carrying out a process selected from processes (A) to (G) followed by interconversion of one or more functional groups.